Skip to main content
Premium Trial:

Request an Annual Quote

BD Says Biosciences Revenue Jumps 9 Percent in Fiscal Q3 as R&D Spend Soars

NEW YORK (GenomeWeb News) – Becton Dickinson today said fiscal third-quarter revenue increased 7 percent as R&D costs soared 42 percent and income grew 9 percent.
 
Receipts for the three months ended June 30 increased to $1.5 billion from $1.4 billion year over year.
 
The BD Biosciences segment reported the strongest growth, as revenues increased 9 percent to $219 million. Sales of flow cytometry instruments, reagents, and cell imaging products contributed to the rise.
 
R&D costs surged 42 percent $276 million from $195 million from the comparable quarter a year ago.
 
Net income for the third quarter increased to $206 million from $190 million during the comparable period last year.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.